VRTX · News · 20260814N
Revenue Performance and Mix
VERTEX PHARMACEUTICALS INC / MA · 2026-08-14 · Importance 54 · Surprise 40 · No source text
Vertex’s cystic fibrosis franchise generated approximately $3.21 billion in Q2 2026 revenue. Franchise revenue increased 10% sequentially and 10.6% year over year. The cystic fibrosis franchise therefore remained the company’s principal reported revenue contributor during the quarter.
Key facts
- Revenue from Vertex's cystic fibrosis franchise in Q2: about $3.21 billion, up 10% quarter-on-quarter and up 10.6% year-on-year. source
- Vertex had an 18.19% total return in the last 90 days. source
- Vertex's share price cited: $558.68 per share and its P/E ratio cited: 29.7x. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +9.2% | Revenue from Vertex's cystic fibrosis franchise in Q2: about $3.21 billion, up 10% quarter-on-quarter and up 10.6% year-on-year. |